Allergan migraine drug succeeds in second late-stage trial
NEW YORK (Reuters) - Allergan Plc on Friday announced positive results from a second Phase III trial for the 50 milligram dose of its drug for acute migraine, reproducing results from the previous trial.
from Reuters: Health News https://reut.rs/2JAaAcl
http://bit.ly/2zwRqiM